Yansun Sun

Prof. Yansun Sun


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
XHXIAO HE
XIAO HE
SXSu Xiong
Su Xiong
YSYansun Sun
Yansun Sun
MZMin Zhong
Min Zhong
NXNianting Xiao
Nianting Xiao
JXJing Xie
Jing Xie
Therapeutic proteins garnered significant attention in the field of disease treatment. In comparison to small molecule drugs, protein therapies offer distinct advantages, including high potency, specificity, low toxicity, and reduced carcinogenicity, even at minimal concentrations. However, the full potential of protein therapy is limited by inherent challenges such as large molecular size, delicate tertiary structure, and poor membrane penetration, resulting in inefficient intracellular delivery into target cells. To address these challenges and enhance the clinical applications of protein therapies, various protein-loaded nanocarriers with tailored modifications were developed, including liposomes, exosomes, polymeric nanoparticles, and nanomotors. Despite these advancements, many of these strategies encounter significant issues such as entrapment within endosomes, leading to low therapeutic efficiency. In this review, we extensively discussed diverse strategies for the rational design of nanocarriers, aiming to overcome these limitations. Additionally, we presented a forward-looking viewpoint on the innovative generation of delivery systems specifically tailored for protein-based therapies. Our intention was to offer theoretical and technical support for the development and enhancement of nanocarriers capable of facilitating cytosolic protein delivery.

16 December 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
XHXiao He
Xiao He
ZWZhongmin Wang
Zhongmin Wang
HBHuayang Bai
Huayang Bai
YTYaqin Tang
Yaqin Tang
DFDaimeng Feng
Daimeng Feng
YSYansun Sun
Yansun Sun

18 December 2025 in Immunologic Research
Verified
Journal Article
Open access
PDF file
YSYansun Sun
Yansun Sun
LWLing Wang
Ling Wang
LLLiu Li
Liu Li
YSYansun Sun
Yansun Sun
Background Cardiovascular-kidney-metabolic (CKM) syndrome is a major public health concern associated with increased mortality. Inflammation plays a critical role in CKM progression and outcomes. This study investigates the relationship between inflammatory indices and mortality risk in CKM patients. Methods A comprehensive analysis of data from 26,265 participants in the National Health and Nutrition Examination Survey (NHANES) database (2007–2016) with CKM syndrome stages 0–4 was conducted. The primary outcomes of the study were all-cause and cardiovascular mortality. The inflammatory indices encompassed the systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), aggregate index of systemic inflammation (AISI), and neutrophil-to-albumin ratio (NAR). Multivariable Cox models, adjusted for demographic and clinical confounders, were employed to examine nonlinearity, alongside restricted cubic splines and threshold analyses. The present study sought to compare the prognostic accuracy of the time-dependent ROC (Receiver Operating Characteristic) at 93 months. Results During a median follow-up of 93.4 months, 2,292 subjects experienced all-cause mortality and 701 experienced cardiovascular deaths. In the adjusted models, elevated SIRI (all-cause HR 1.11, 95% CI 1.06–1.15; cardiovascular HR 1.18, 1.10–1.27), NLR (all-cause HR 1.08, 1.05–1.12; cardiovascular HR 1.11, 1.05–1.17) and MLR (all-cause HR 2.27, 1.71–3.01; cardiovascular HR 3.37, 2.09–5.44) were independently associated with mortality (all p < 0.0001). Dose–response analyses revealed nonlinear J-shaped relationships: MLR showed marked risk above 0.19 (HR 2.59), NLR risk was greatest below 3 (HR 1.14), and SIRI thresholds differed for all-cause (> 1.74, HR 1.09) versus cardiovascular (> 0.38, HR 1.17) outcomes. At 93 months, MLR demonstrated the highest discriminatory ability (AUC 0.630; C-index 0.667; p < 0.001), outperforming SIRI (AUC 0.611) and NLR (AUC 0.602). PLR, AISI, SII and NAR showed limited predictive value due to imbalanced sensitivity–specificity. The impact of age and the early stages of CKD on the modification of associations was investigated. Conclusion Systemic inflammatory indices demonstrated nonlinear, J-shaped associations with mortality in CKM syndrome, with the MLR showing the strongest association across disease trajectories. MLR, NLR, and SIRI were identified as potential risk indicators, with stronger associations observed in younger patients and those with early-stage CKM syndrome. Highlights Systemic inflammatory markers (SIRI, NLR, MLR) were significantly associated with increased mortality risk in CKM syndrome. Most inflammation indices exhibited nonlinear, J-shaped associations with mortality. Nonlinear threshold analyses identified specific risk inflection points for SIRI, NLR, and MLR. These associations were stronger in younger patients (≤ 60 years) and those with early CKM stages (1–2).

29 August 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ZWZhongmin Wang
Zhongmin Wang
XHXiao He
Xiao He
HBHuayang Bai
Huayang Bai
DFDaimeng Feng
Daimeng Feng
YQYannv Qu
Yannv Qu
YSYansun Sun
Yansun Sun

Verified
Journal Article
Open access
PDF file
XHXIAO HE
XIAO HE
YSYansun Sun
Yansun Sun
SXSu Xiong
Su Xiong
ZJZhiru Jiang
Zhiru Jiang
YTyaqin tang
yaqin tang
YSYansun Sun
Yansun Sun
The utilization of cytosolic protein delivery is a promising approach for treating various diseases by replacing dysfunctional proteins. Despite the development of various nanoparticle-based intracellular protein delivery methods, the complicated chemical synthesis of the vector, loading efficiency and endosomal escape efficiency of proteins remain a great challenge. Recently, 9-fluorenylmethyloxycarbonyl (Fmoc)-modified amino acid derivatives have been used to self-assemble into supramolecular nanomaterials for drug delivery. However, the instability of the Fmoc group in aqueous medium restricts its application. To address this issue, the Fmoc ligand neighboring arginine was substituted for dibenzocyclooctyne (DBCO) with a similar structure to Fmoc to obtain stable DBCO-functionalized L-arginine derivative (DR). Azide-modified triethylamine (crosslinker C) was combined with DR to construct self-assembled DRC via a click chemical reaction for delivering various proteins, such as BSA and saporin (SA), into the cytosol of cells. The hyaluronic-acid-coated DRC/SA was able to not only shield the cationic toxicity, but also enhance the intracellular delivery efficiency of proteins by targeting CD44 overexpression on the cell membrane. The DRC/SA/HA exhibited higher growth inhibition efficiency and lower IC50 compared to DRC/SA toward various cancer cell lines. In conclusion, DBCO-functionalized L-arginine derivative represents an excellent potential vector for protein-based cancer therapy.

26 June 2026 in Medicine
Verified
Journal Article
Open access
YSYansun Sun
Yansun Sun
LWLing Wang
Ling Wang
ZLZhiwei Li
Zhiwei Li
LLLi Liu
Li Liu
YSYansun Sun
Yansun Sun
The relationship between serum uric acid (UA) and mortality in patients with cardiovascular-kidney-Metabolic (CKM) syndrome remains unclear. We hypothesized that elevated UA increases mortality nonlinearly and is partly mediated by vitamin D. Using NHANES data (2007–2016) from 25,979 adults with CKM stages 0 to 4, we performed Cox regression, threshold analysis, and causal mediation analysis. During a median follow-up of 93.0 months, 2264 all-cause and 689 cardiovascular deaths occurred. A J-shaped relationship existed between UA and mortality. Each 1 mg/dL increase in UA increased fully adjusted risks of all-cause (HR = 1.06, 95% CI: 1.02–1.09) and cardiovascular mortality (HR = 1.11, 95% CI: 1.04–1.18). Thresholds were identified at 6.6 mg/dL and 7.1 mg/dL. Participants aged ≤60 years showed higher all-cause mortality risk (HR = 1.15, 95% CI: 1.06–1.25). Serum 25(OH)D negatively correlated with UA (β = −0.064, P < .00001) and mediated 14.55% of its effect on all-cause mortality. High UA beyond specific thresholds predicts mortality in CKM syndrome, partially mediated by vitamin D. Interventions on UA and vitamin D may improve outcomes.